Inherited gene variants may shape CAR-T therapy benefits and toxic side effects

Researchers at the Mass General Brigham Cancer Institute, the Broad Institute of MIT and Harvard, and Dana-Farber Cancer Institute have made a significant breakthrough in understanding the impact of CAR-T cell therapy on patients with blood cancers. This groundbreaking treatment, which reprograms an individual's immune cells to target and destroy cancer cells, has shown remarkable promise in treating lymphoma and other blood-related cancers. However, some patients have experienced severe side effects from the therapy, prompting scientists to investigate the underlying factors contributing to these outcomes.

A new study published in Science Immunology reveals that a patient's inherited genetic makeup plays a crucial role in determining whether they benefit from CAR-T cell therapy or experience toxicity from the treatment. The research suggests that certain genetic variations can influence the effectiveness of CAR-T cell therapy, with some patients being more likely to benefit from the treatment while others may be at a higher risk of experiencing adverse reactions. This finding has significant implications for the development of personalized treatment strategies, allowing clinicians to tailor therapy to individual patients based on their unique genetic profiles.

The discovery of this genetic link has the potential to revolutionize the field of CAR-T cell therapy, enabling healthcare providers to better predict which patients are likely to respond well to the treatment and which may require alternative approaches. As researchers continue to unravel the complexities of this therapy, patients with blood cancers may benefit from more effective and safer treatment options in the future.